Amgen Posts Mixed Third-Quarter Results, Sales of Epogene Nosedive
publication date: Oct 24, 2011
Amgen's third-quarter results were mixed, as revenue and earnings growth was overshadowed by a legal charge and weakness with Epogene. We think the company looks cheap, but are waiting cautiously for improvement in its score on our Valuentum Buying Index.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.